Evidence map›Paper›PMID 35061057›Full record

GuidelineJournal of gastroenterology2022

Evidence-based clinical practice guidelines for functional dyspepsia 2021.

Hiroto Miwa, Akihito Nagahara, Akihiro Asakawa, Makoto Arai, Tadayuki Oshima, Kunio Kasugai, Kazuhiro Kamada, Hidekazu Suzuki, Fumio Tanaka, Kazunari Tominaga and 12 more

Registry-linked trialOpen access · hybridAbstract readPractice GuidelineReview
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07694778 (Prevalence of Functional Dyspepsia in Rural Community of Bangladesh), which is not on this map. Cited by 66 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 8 pooled it
24.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07694778 recruitingnot on this mapstarted 2026, after this paper: background citation

Prevalence of Functional Dyspepsia in Rural Community of Bangladesh: A Cross Sectional Study

TypeobservationalSponsorBangladesh Medical UniversityRan2026 to 2026Enrolled730ConditionsFunctional Dyspepsia
3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 8 syntheses or guidelines pooled it, 114 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Therapeutic massage/Tuina for treatment of functional dyspepsia: a systematic review and meta-analysis of randomized controlled trials.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023
    Pooled it
  8. Pooled it
  9. Trial
  10. Physical Activity as a Therapeutic Strategy for Functional Dyspepsia.Journal of neurogastroenterology and motility · 2026
    Article
  11. Article
  12. Gastric cancer secondary prevention in dyspeptic patients.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Article
  13. Article
  14. Article
  15. Review
  16. Acid peptic disorder compass: An Indian expert consensus on comprehensive management.World journal of gastrointestinal pharmacology and therapeutics · 2026
    Review
  17. Dyspepsia followingWorld journal of gastroenterology · 2026
    Article
  18. Review
  19. Article
  20. Pharmaceutical biology · 2025
    Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 1 institution in 1 country.

Hiroto MiwaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Functional Dyspepsia", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan. miwahgi@hyo-med.ac.jp.
Akihito NagaharaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Functional Dyspepsia", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Akihiro AsakawaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Functional Dyspepsia", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Makoto AraiGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Functional Dyspepsia", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Tadayuki OshimaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Functional Dyspepsia", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Kunio KasugaiGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Functional Dyspepsia", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Kazuhiro KamadaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Functional Dyspepsia", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Hidekazu SuzukiGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Functional Dyspepsia", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Fumio TanakaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Functional Dyspepsia", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Kazunari TominagaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Functional Dyspepsia", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Seiji FutagamiGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Functional Dyspepsia", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Mariko HojoGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Functional Dyspepsia", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Hiroshi MiharaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Functional Dyspepsia", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Kazuhide HiguchiGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Functional Dyspepsia", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Motoyasu KusanoGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Functional Dyspepsia", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Tomiyasu ArisawaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Functional Dyspepsia", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Mototsugu KatoGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Functional Dyspepsia", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Takashi JohGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Functional Dyspepsia", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Satoshi MochidaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Functional Dyspepsia", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Nobuyuki EnomotoGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Functional Dyspepsia", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Tooru ShimosegawaGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Functional Dyspepsia", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
Kazuhiko KoikeGuidelines Committee for Creating and Evaluating the "Evidence-Based Clinical Practice Guidelines for Functional Dyspepsia", The Japanese Society of Gastroenterology, 6F Shimbashi i-MARK Building, 2-6-2 Shimbashi, Minato-ku, Tokyo, 105-0004, Japan.
The Japanese Society of Gastroenterological Surgery · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFunctional dyspepsia (FD) is a disorder that presents with chronic dyspepsia, which is not only very common but also highly affects quality of life of the patients. In Japan, FD became a disease name for national insurance in 2013, and has been gradually recognized, though still not satisfactory. Following the revision policy of Japanese Society of Gastroenterology (JSGE), the first version of FD guideline was revised this time.

methodLike previously, the guideline was created by the GRADE (grading of recommendations assessment, development and evaluation) system, but this time, the questions were classified to background questions (BQs, 24 already clarified issues), future research questions (FRQs, 9 issues cannot be addressed with insufficient evidence), and 7 clinical questions that are mainly associated with treatment. RESULTS AND

conclusionThese revised guidelines have two major features. The first is the new position of endoscopy in the flow of FD diagnosis. While endoscopy was required to all cases for diagnosis of FD, the revised guidelines specify the necessity of endoscopy only in cases where organic disease is suspected. The second feature is that the drug treatment options have been changed to reflect the latest evidence. The first-line treatment includes gastric acid-secretion inhibitors, acetylcholinesterase (AChE) inhibitors (acotiamide, a prokinetic agent), and Japanese herbal medicine (rikkunshito). The second-line treatment includes anxiolytics /antidepressant, prokinetics other than acotiamide (dopamine receptor antagonists, 5-HT4 receptor agonists), and Japanese herbal medicines other than rikkunshito. The patients not responding to these treatment regimens are regarded as refractory FD.

Indexed as

DyspepsiaGastroenterologyHelicobacter InfectionsAcetylcholinesteraseEndoscopy, GastrointestinalHumansQuality of LifeAcetylcholinesteraseAlgorithmAntianxiety drugAntidepressantChronic gastritisDyspepsiaGuidelineH. pylori-associated dyspepsiaH. pylori eradication treatmentJapanese traditional medicineProkineticsProton pump inhibitor

Identifiers

PMID35061057
PMCPMC8831363
OpenAlexW4205215890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.